Pharmaceutical Executive February 5, 2025
Mike Hollan

Hiroyuki Okuzawa will step into the role starting in April.

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025.1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and executive chairperson.

Okuzawa will also serve as representative director and president. Prior to this, he served as chief operating officer of the company.

In a press release, Okuzawa said, “I am deeply honored to be the next CEO of Daiichi Sankyo and will follow Sunao Manabe’s exceptional leadership and unwavering commitment to patients and their families. Building on this foundation, I will continue to leverage Daiichi Sankyo’s strengths in science and technology, and will continuously develop our talent...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Related Articles:
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Ono pays $280M to license Ionis rare disease drug

Share This Article